source
- Novo to pay up to $2.6 billion for rights to Hengrui’s experimental weekly obesity pillNovo Pharmaceuticals has signed a licensing agreement with China's Hengrui Pharma to acquire an experimental oral weight‑loss drug that is administered once a week. Under the deal, Novo could pay…
- ARCH Venture Partners and Population Health Partners launch China-based sleep-disorder startup SomniveraARCH Venture Partners and Population Health Partners have teamed up again to create a new China-focused biotech, Somnivera, aimed at developing therapies for sleep disorders. The partnership follo…